KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Operating Income (2016 - 2025)

Neogenomics' Operating Income history spans 16 years, with the latest figure at -$13.4 million for Q4 2025.

  • For Q4 2025, Operating Income rose 27.1% year-over-year to -$13.4 million; the TTM value through Dec 2025 reached -$115.9 million, down 25.81%, while the annual FY2025 figure was -$115.9 million, 25.81% down from the prior year.
  • Operating Income reached -$13.4 million in Q4 2025 per NEO's latest filing, up from -$27.0 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of -$13.4 million in Q4 2025 to a low of -$52.0 million in Q1 2022.
  • Average Operating Income over 5 years is -$29.6 million, with a median of -$27.4 million recorded in 2025.
  • Peak YoY movement for Operating Income: crashed 950.57% in 2021, then skyrocketed 38.76% in 2023.
  • A 5-year view of Operating Income shows it stood at -$41.6 million in 2021, then soared by 36.53% to -$26.4 million in 2022, then rose by 29.6% to -$18.6 million in 2023, then rose by 0.93% to -$18.4 million in 2024, then rose by 27.1% to -$13.4 million in 2025.
  • Per Business Quant, the three most recent readings for NEO's Operating Income are -$13.4 million (Q4 2025), -$27.0 million (Q3 2025), and -$47.6 million (Q2 2025).